What technology area does this patent fall under?

Primary CPC classification C07K7/06. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

US9226974B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9226974-B2
Application number	US-201414324480-A
Country	US
Kind code	B2
Filing date	Jul 7, 2014
Priority date	Aug 3, 2009
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Antiproliferative compounds having a structure represented by formula (II), where n, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:

First claim

Opening claim text (preview).

What is claimed is: 1. A conjugate having a structure according to the formula where Ab represents an antibody. 2. A conjugate according to claim 1 , wherein Ab is a monoclonal antibody. 3. A conjugate according to claim 1 , wherein Ab is a human monoclonal antibody. 4. A conjugate according to claim 1 , wherein Ab is an anti-PSMA (prostate specific membrane antigen) antibody, an anti-CD70 antibody, or an anti-mesothelin antibody. 5. A conjugate according to claim 1 , wherein Ab is an anti-CD70 antibody. 6. A conjugate according to claim 5 , wherein the anti-CD70 antibody is antibody 2H5. 7. A conjugate according to claim 1 , wherein Ab is an anti-mesothelin antibody. 8. A conjugate according to claim 7 , wherein the anti-mesothelin antibody is antibody 6A4.

Assignees

Squibb & Sons Llc

Inventors

Classifications

A61P35/02
specific for leukemia · CPC title
A61P35/04
specific for metastasis · CPC title
A61P35/00
Antineoplastic agents · CPC title
C07K7/06Primary
having 5 to 11 amino acids · CPC title
C07D417/14
containing three or more hetero rings · CPC title

Patent family

Related publications grouped by family.

View patent family 42782224

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9226974B2 cover?: Antiproliferative compounds having a structure represented by formula (II), where n, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
Who is the assignee on this patent?: Squibb & Sons Llc
What technology area does this patent fall under?: Primary CPC classification C07K7/06. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).